Comparative Pharmacology
Head-to-head clinical analysis: DELFLEX W DEXTROSE 4 25 LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER versus DELFLEX LM W DEXTROSE 3 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELFLEX W DEXTROSE 4 25 LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER versus DELFLEX LM W DEXTROSE 3 5 IN PLASTIC CONTAINER.
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER vs DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Delflex with 4.25% dextrose is a peritoneal dialysis solution that removes waste products, electrolytes, and excess fluid from the blood via diffusion and ultrafiltration across the peritoneal membrane. Dextrose creates an osmotic gradient, drawing fluid and solutes from the capillaries into the peritoneal cavity.
DELFLEX-LM W/ DEXTROSE 3.5% is a peritoneal dialysis solution. Its mechanism of action involves osmotic ultrafiltration across the peritoneal membrane, facilitated by high dextrose concentration, to remove excess fluid and waste products (e.g., urea, creatinine) from the blood in patients with end-stage renal disease.
Continuous ambulatory peritoneal dialysis (CAPD)Continuous cycling peritoneal dialysis (CCPD)Automated peritoneal dialysis (APD)Management of end-stage renal disease (ESRD)
FDA-approved for use as a peritoneal dialysis solution in continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD) for patients with acute or chronic renal failure.Off-label: management of fluid overload in patients with heart failure resistant to diuretics (rare).
Intraperitoneal administration: 2 to 2.5 liters per exchange, 4 to 5 exchanges per day, as part of continuous ambulatory peritoneal dialysis (CAPD).
Intraperitoneal: 1.5% to 4.25% dextrose solution; 2 to 2.5 L per exchange, typically 4 exchanges per 24 hours; dwell time 4 to 6 hours.
None Documented
None Documented
Not applicable as a combination solution; glucose half-life ~1.5-2 hours in normal renal function; prolonged in renal impairment.
Not applicable for dextrose; for lactate/bicarbonate buffer components, half-life is approximately 2-4 hours in peritoneal cavity with systemic absorption minimal. Clinical context: continuous dialysis maintains steady-state.
Dextrose is absorbed systemically and metabolized via glycolysis and the Krebs cycle. No hepatic metabolism for the solution components; waste removal is achieved through peritoneal dialysis. Insulin may be required to manage hyperglycemia.
Dextrose is metabolized via glycolysis and the citric acid cycle to carbon dioxide and water, with some absorption from the peritoneal cavity. Lactate (from the buffer) is metabolized primarily in the liver to bicarbonate.
Renal: >90% as unchanged glucose and electrolytes; negligible biliary/fecal elimination.
Peritoneal dialysis: Removal of waste products (urea, creatinine) via peritoneal membrane; approximately 60-80% of urea is removed during a 4-6 hour dwell. Biliary/fecal: minimal (<5%). Renal: negligible as drug is primarily used in renal failure.
Minimal (<10%); glucose and electrolytes do not significantly bind to plasma proteins.
Dextrose: negligible (<5%); electrolytes: negligible. Peritoneal dialysis solutions per se do not have significant protein binding.
Glucose: ~0.2 L/kg (extracellular fluid); electrolytes distribute according to body water compartments.
Dextrose distributes in total body water (approximately 0.6 L/kg); for dialysate, distribution into peritoneal cavity volume is 2-3 L.
Intraperitoneal: ~70-80% for glucose absorption; electrolytes 100% bioavailable via peritoneal route.
Intraperitoneal: 100% for local effects; systemic absorption of glucose occurs (approximately 60-80% of glucose load) via peritoneal capillaries.
Not applicable; drug is used for renal replacement therapy in end-stage renal disease.
Deliver via peritoneal dialysis; no dose adjustment necessary as drug is administered intraperitoneally for renal replacement therapy.
No specific adjustments; monitor for metabolic acidosis and electrolyte imbalances in severe hepatic impairment.
No specific dose adjustment; monitor for signs of hepatic encephalopathy or fluid overload in severe hepatic impairment.
Weight-based: 30 to 40 mL/kg per exchange, 4 to 5 exchanges per day; adjust based on residual renal function and ultrafiltration needs.
Intraperitoneal: 20 to 40 mL/kg per exchange (typical fill volume 800-1100 mL/m2), 4 to 5 exchanges per 24 hours; dwell time 2 to 6 hours per exchange.
No specific dose adjustments; monitor glucose and electrolyte levels closely due to higher risk of hyperglycemia and fluid overload.
No specific dose adjustment; monitor for fluid and electrolyte balance, and adjust dextrose concentration based on ultrafiltration needs and glucose tolerance.
Peritoneal dialysis solutions with dextrose, including Delflex with 4.25% dextrose, are contraindicated in patients with pre-existing severe hyperglycemia or who are hypersensitive to any component of the product. The solution is for peritoneal administration only, not for intravenous use. Strict sterile technique in catheter placement and fluid exchange is required to prevent peritonitis.
None.
["Hyperglycemia and hyperosmolar syndrome, especially in patients with diabetes mellitus","Peritonitis and exit-site infections; strict aseptic technique required","Electrolyte imbalances (hypokalemia, hypomagnesemia, hypocalcemia) due to low magnesium and low calcium formulation","Protein loss and malnutrition","Fluid overload or dehydration (monitor fluid balance)","Hernias and abdominal discomfort","Peritoneal catheter complications"]
Risk of peritonitis, abdominal pain, electrolyte disturbances (e.g., hyperglycemia, hypernatremia, hypokalemia), fluid overload, and metabolic acidosis. Use with caution in patients with severe hyponatremia, hypokalemia, or impaired liver function.
["Hypersensitivity to any component","Pre-existing severe hyperglycemia or uncontrolled diabetes","Peritoneal adhesions, fibrosis, or sclerosis","Abdominal wall infection or peritonitis","Recent abdominal surgery or trauma","Severe pulmonary disease (risk of respiratory compromise)","Collagen vascular disease (e.g., scleroderma)","Uncorrectable mechanical defects (e.g., catheter malfunction)"]
Hypersensitivity to any component; pre-existing hyperglycemia; severe hyponatremia; hypokalemia; hyperlactatemia; or conditions with increased peritoneal permeability (e.g., peritonitis, severe burns).
Data Pending Review
Data Pending Review
No direct food interactions, but patients on peritoneal dialysis may require dietary restrictions for potassium, phosphorus, and sodium. Avoid excessive intake of calcium- or magnesium-rich foods (e.g., dairy, nuts, leafy greens) if monitoring indicates imbalances. Dextrose absorption may affect blood glucose; manage carbohydrate intake accordingly.
Dietary restrictions typically include low sodium, low potassium, and low phosphorus intake to manage fluid and electrolyte balance. Avoid high-sugar foods if hyperglycemia develops. Consult a renal dietitian for individualized meal planning.
Delflex w/ Dextrose 4.25% Low Magnesium Low Calcium is a peritoneal dialysis solution. There are no adequate studies in pregnant women. Peritoneal dialysis itself may pose risks (e.g., infection, preterm labor). Dextrose may cause maternal hyperglycemia and fetal hyperinsulinism. Use only if clearly needed, weighing risks vs benefits. Trimester-specific risks are not established; reports of congenital anomalies are not directly attributed to the solution.
No evidence of teratogenicity in animal studies; human data are lacking. However, in case of severe maternal electrolyte disturbances or infection, potential indirect fetal risks may arise. Generally considered low risk if administered appropriately.
It is unknown whether Delflex components are excreted in human milk. Dextrose and electrolytes are endogenous substances. The M/P ratio is not available. Caution is advised; consider risk of infant exposure to small amounts of dialysate components.
Excretion into breast milk is expected to be minimal due to high molecular weight, but specific M/P ratio not reported. Compatible with breastfeeding if maternal therapy is necessary; caution due to possible high glucose load in neonates.
No specific dose adjustment recommendations during pregnancy. Pharmacokinetic changes (e.g., increased volume of distribution, altered electrolyte needs) may require careful monitoring and adjustment of exchange volume, frequency, and electrolyte composition to maintain metabolic control. Consult nephrology for individualized therapy.
Standard dosing may be used; however, pregnancy-induced hypervolemia and increased glomerular filtration rate may require adjustment of exchange volumes and dextrose concentration to maintain electrolyte and glucose homeostasis. Close monitoring of maternal weight, blood pressure, and serum chemistries is recommended.
Category C
Category C
This solution is used in peritoneal dialysis. The low magnesium and low calcium formulation is indicated for patients with hypermagnesemia or hypercalcemia, or to adjust electrolyte balance. Monitor serum magnesium and calcium levels regularly. The 4.25% dextrose concentration provides higher ultrafiltration; use with caution in patients with hyperglycemia or insulin-dependent diabetes. Check for solution cloudiness or leaks before use. Warm solution to body temperature before infusion to reduce discomfort.
This is a peritoneal dialysis solution containing 3.5% dextrose. Use the lowest dextrose concentration necessary for adequate ultrafiltration to avoid hyperglycemia and metabolic complications. Warm the solution to body temperature before administration to reduce patient discomfort. Monitor serum electrolytes, glucose, and urea regularly. Do not use if solution is discolored or contains particulates.
Follow strict sterile technique during bag exchange to prevent peritonitis.Check the solution for clarity, color, and leaks before use.Warm the solution to body temperature before infusion for comfort.Monitor for signs of infection (abdominal pain, fever, cloudy effluent) and report immediately.Keep a log of your weight, blood pressure, and inflow/outflow volumes.Do not modify the solution composition without consulting your healthcare provider.
Store the solution at room temperature and protect from light.Warm the bag to body temperature before use for comfort.Inspect the solution for clarity and discard if cloudy or containing particles.Follow aseptic technique to prevent peritonitis.Report any signs of infection (fever, abdominal pain, cloudy effluent) immediately.